{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-015894","form_type":"8-K","ticker":"CTOR","cik":"0001851484","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2026-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.537167+00:00","generated_at":"2026-05-16T02:49:46.338292+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Citius Oncology reports first revenue of $3.9M from LYMPHIR launch; net loss narrows to $5.5M","bullets":["Revenue of $3.9M for Q1 FY2026 ended Dec 31, 2025, first reported sales following December 2025 commercial launch of LYMPHIR.","Net loss of $5.5M ($0.06 per share) improved from $6.7M loss ($0.09) in prior-year period.","Cash and equivalents $7.3M as of Dec 31, 2025; raised net proceeds of ~$15.1M via December 2025 registered offering.","LYMPHIR (denileukin diftitox-cxdl) launched for relapsed/refractory Stage I-III cutaneous T-cell lymphoma; patient initiations underway at leading U.S. cancer centers.","AI-enabled commercial platform deployed; international access advanced through regional distribution partners in Europe and Middle East."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-015894","json":"https://secwatch.observer/filing/0001213900-26-015894.json","markdown":"https://secwatch.observer/filing/0001213900-26-015894.md","text":"https://secwatch.observer/filing/0001213900-26-015894.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026015894/0001213900-26-015894-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026015894/ea0276947-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:49:46.338292+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}